diphenylamine has been researched along with pyrimidinones in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 7 (77.78) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Akyel, KG; Albert, R; Beerli, C; Bruns, C; Francotte, E; Luyten, M; MacKenzie, D; Nuninger, F; Oberer, L; Schaefer, M; Streiff, MB; Thoma, G; Wagner, T; Walter, H; Weckbecker, G; Zerwes, HG | 1 |
| Hantani, Y; Kakegawa, J; Nakamura, M; Okajima, N; Sakai, T; Watanabe, Y; Yamaguchi, T; Yoshida, T | 1 |
| Fellmann, C; Gadal, S; Ishii, N; Joseph, E; Kastenhuber, E; Lito, P; Lowe, S; Lukacs, C; Miura, T; Morikami, K; Ohara, K; Rosen, N; Saborowski, A; Saborowski, M; Solomon, M; Yue, J | 1 |
| Banks, AS; Beausoleil, SA; Everley, RA; Gygi, SP; McAllister, FE; Paulo, JA | 1 |
| Kim, MS | 1 |
| Kiessling, MK; Rogler, G | 1 |
| Banno, E; Chiba, M; De Velasco, MA; Fujita, Y; Hayashi, H; Mitsudomi, T; Mizuuchi, H; Nakamura, Y; Nishio, K; Sakai, K; Terashima, M; Togashi, Y; Tomida, S | 1 |
| Bago-Horvath, Z; Fece de la Cruz, F; Haura, EB; Katz, AM; Kerzendorfer, C; Konopka, T; Loizou, JI; Mair, B; Mazouzi, A; Muellner, MK; Nagy-Bojarszky, K; Nijman, SM; Paz, K; Smida, M; Suchankova, T; Uras, IZ | 1 |
| Mergener, S; Peña-Llopis, S; Siveke, JT | 1 |
1 review(s) available for diphenylamine and pyrimidinones
| Article | Year |
|---|---|
Targeting the RAS pathway by mitogen-activated protein kinase inhibitors.
Topics: Animals; Azetidines; Benzamides; Benzimidazoles; Diphenylamine; Genes, ras; GTP Phosphohydrolases; Humans; Membrane Proteins; Mice; Mitogen-Activated Protein Kinases; Mutation; Neoplasms; Niacinamide; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Pyridones; Pyrimidinones; Signal Transduction; Sulfonamides | 2015 |
8 other study(ies) available for diphenylamine and pyrimidinones
| Article | Year |
|---|---|
Orally bioavailable competitive CCR5 antagonists.
Topics: Administration, Oral; Animals; Biological Availability; Calcium; CCR5 Receptor Antagonists; Cell Line; Chemotaxis, Leukocyte; Cricetinae; Crystallography, X-Ray; Cyclic N-Oxides; Diphenylamine; Humans; In Vitro Techniques; Lymphocytes; Macaca fascicularis; Mice; Molecular Structure; Piperidines; Pyrimidines; Pyrimidinones; Radioligand Assay; Rats; Structure-Activity Relationship | 2004 |
Identification and characterization of a novel chemotype MEK inhibitor able to alter the phosphorylation state of MEK1/2.
Topics: Allosteric Regulation; Antineoplastic Agents; Benzamides; Butadienes; Chromatography, Affinity; Diphenylamine; Dose-Response Relationship, Drug; HEK293 Cells; HT29 Cells; Humans; Kinetics; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Molecular Structure; Molecular Targeted Therapy; Neoplasms; Nitriles; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Signal Transduction | 2012 |
Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors.
Topics: Animals; Benzamides; Cell Line; Coumarins; Diphenylamine; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; HEK293 Cells; Humans; Indoles; MAP Kinase Kinase 1; MAP Kinase Signaling System; Melanoma; Mice; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Pyridones; Pyrimidinones; raf Kinases; ras Proteins; RNA Interference; RNA, Small Interfering; Sulfonamides; Surface Plasmon Resonance; TNF Receptor-Associated Factor 3; Vemurafenib | 2014 |
Effects of MEK inhibitors GSK1120212 and PD0325901 in vivo using 10-plex quantitative proteomics and phosphoproteomics.
Topics: Amino Acid Sequence; Animals; Benzamides; Diphenylamine; Humans; Kidney; Liver; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Molecular Sequence Data; Pancreas; Phosphopeptides; Phosphorylation; Protein Kinase Inhibitors; Proteome; Proteomics; Pyridones; Pyrimidinones; Tandem Mass Spectrometry | 2015 |
Proteomics equipped with multiplexing toward ultra high throughput.
Topics: Animals; Benzamides; Diphenylamine; Humans; Mitogen-Activated Protein Kinase Kinases; Phosphopeptides; Protein Kinase Inhibitors; Proteome; Pyridones; Pyrimidinones | 2015 |
MEK inhibitors against MET-amplified non-small cell lung cancer.
Topics: A549 Cells; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crizotinib; Diphenylamine; ErbB Receptors; Humans; Lung Neoplasms; MAP Kinase Kinase 1; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyridones; Pyrimidinones | 2016 |
MEK inhibitors block growth of lung tumours with mutations in ataxia-telangiectasia mutated.
Topics: Animals; Ataxia Telangiectasia Mutated Proteins; Benzamides; Cell Line, Tumor; Cell Proliferation; Diphenylamine; Humans; Lung Neoplasms; Mice, Nude; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; ras Proteins; RNA Interference; Thiophenes; Urea; Xenograft Model Antitumor Assays | 2016 |
Monosomy 3 Is Linked to Resistance to MEK Inhibitors in Uveal Melanoma.
Topics: Cell Line, Tumor; Chromosomes, Human, Pair 3; Diphenylamine; DNA Copy Number Variations; Drug Resistance, Neoplasm; Eukaryotic Initiation Factor-2; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Melanoma; Mitogen-Activated Protein Kinase Kinases; Monosomy; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Sulfonamides; Survival Analysis; Tumor Suppressor Proteins; Ubiquitin Thiolesterase; Uveal Neoplasms | 2021 |